Biomarker Core

马萨诸塞州阿尔茨海默病研究中心：生物标记物核心 马萨诸塞州阿尔茨海默病研究中心(MADRC)的Biomarker Core支持和 进行生物流体生物标记物研究，有助于我们了解阿尔茨海默氏症的异质性 此外，我们还将继续努力防治与阿尔茨海默病和阿尔茨海默病相关的疾病(AD/ADRD)，并加快治疗进展。 我们履行核心职能，整合资源，通过目标1加强研究任务，S 血液和脑脊液(CSF)收集、管理和分发活动 国家研究和目标2‘S标准化淀粉样蛋白必要分子诊断方法的性能- B42和tau将为MADRC研究队列和其他组织中AD/ADRD的生物学分类做出贡献 样本。我们制定和实施了新的战略，并加快了在目标3和 4‘S改进和验证针对多种病理生理指标的新型ELISA法、SIMA法和MS法 血液和脑脊液中的途径，以及在Aim 5‘S表达的重点是了解这些检测方法在临床和 临床试验设置。这些新方法在MADRC的血液和脑脊液采集中进行了试验 涵盖不同的AD/ADRD诊断、疾病阶段、预后、人口学(包括性别 生物变量)、风险因素、不同的病理生理驱动因素和治疗。成功试行 然后利用工作和生物流体样本资源来促进更大规模的重点研究项目 在MADRC社区之外。我们通过提供专业知识、教育和培训来建设目标6的未来 为教师、学员和学生提供生物流体生物标记物研究最佳实践的实验室资源， 在目标7中，通过向研究人员、临床医生和公众提供关于先进、实用和 ADRD研究中对生物标记物数据的负责任的解释，以及最终如何将生物标记物用于 照顾AD/ADRD患者。

Massachusetts Alzheimer’s Disease Research Center: Biomarker Core The Biomarker Core of the Massachusetts Alzheimer’s Disease Research Center (MADRC) supports and performs biofluid biomarker research to contribute to our understanding heterogeneity in Alzheimer’s disease and Alzheimer’s disease related disorders (AD/ADRD) and to accelerate progress towards a cure. We carry out core functions, marshaling resources to enhance the research mission through Aim 1's collection, curation and distribution activities for blood and cerebrospinal fluids (CSF) for MADRC, local and national research and Aim 2's standardized performance of essential molecular diagnostic assays of amyloid- b42 and tau to contribute to biological classification of AD/ADRDs in the MADRC Research Cohort and other samples. We develop and implement new strategies and accelerate progress towards a cure in Aim 3 and 4's refinement and validation of novel ELISA, Simoa, and MS assays targeting multiple pathophysiological pathways in blood and CSF, and in Aim 5's express focus on understanding those assays' utility for clinical and clinical trials settings. These novel approaches are piloted in the MADRC collections of blood and CSF spanning diverse AD/ADRD diagnoses, stages of disease, prognosis, demography (including sex as a biological variable), risk factors, heterogeneous pathophysiological drivers, and treatment. Successful pilot work and biofluid sample resources are then leveraged to facilitate larger focused research projects in and outside of the MADRC community. We build the future in Aim 6 by providing expertise, education, training and laboratory resources to faculty, trainees and students for best practices in biofluids biomarker research, and in Aim 7 by providing education to researchers, clinicians and the public on the advances, utility and responsible interpretation of biomarker data in ADRD research and ultimately how biomarkers can be used in caring for people with AD/ADRD.